We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData, Phase I drugs for Soft Tissue Sarcoma have an 83% phase transition ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago.

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers ...

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today ...

Pyxis Technology created analog routing engines. Pyxis Technology enables assisted custom design automation with integrated analysis for ‘what-if’ exploration of custom analog design, and fast, ...

As of May 01, 2024, Pyxis Oncology Inc had a $258.7 million market capitalization, putting it in the 47th percentile of companies in the Biotechnology & Medical Research industry. Pyxis Oncology Inc ...

Pyxis Oncology, Inc. (NASDAQ: PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago ...

This web version of the DATA VANTAGE twice-weekly premium newsletter is available only to our premium subscribers. Unlock access by picking up any of our premium subscription plans. Subscribe now to ...

Pyxis Oncology Inc has a consensus price target of $12.67, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Jefferies ...